Choate Investment Advisors Acquires 102 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Choate Investment Advisors raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 11.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,022 shares of the medical research company’s stock after buying an additional 102 shares during the quarter. Choate Investment Advisors’ holdings in IQVIA were worth $201,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Private Trust Co. NA increased its holdings in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co increased its holdings in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares during the period. Howard Capital Management Inc. increased its holdings in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares during the period. Huntington National Bank increased its holdings in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after buying an additional 56 shares during the period. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IQV has been the topic of several research reports. Barclays decreased their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. UBS Group decreased their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

Shares of NYSE:IQV opened at $184.64 on Tuesday. The company’s 50-day moving average is $196.34 and its 200 day moving average is $209.96. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $32.55 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.